1. Khoshnood B, Grenlees R, Loane M, Dolk A. Paper 2: EUROCAT public health indicators for congenital anomalies in Europe. Birth Defects Res Part A Clin Mol Teratol. 2011;91(1):S16–22.
2. Fortuny A, Gomez ML, Ortega MD, Montalvo J, Valero J, Troyano J, Mercé L, Martínez O, Lozano C. Combined screening test nationwide proposal for the detection of chromosomopaties in the first trimester of pregnancy. Recommendations for the Organization of Obstetric and Gynaecological Services. SEGO Document. 2005.
http://www.aebm.org/documentos/screening%20gestante.pdf
. Accessed 3 Aug 2018.
3. López de Argumedo M, Egües N, Lapuente JL. Prenatal screening of Down syndrome. Vitoria-Gasteiz: Ministry of Health, Basque Government, Health Technology Assessment report. 2007. Osteba D-07-04.
https://www.osakidetza.euskadi.eus/contenidos/informacion/2007_osteba_publicacion/es_def/adjuntos/d_07-04_inform_SinDown.pdf
. Accessed 3 Aug 2018.
4. Nicolaides KH. Screening for fetal aneuploidies at 11 to 13 weeks. Prenat Diagn. 2011;31:7–15.
5. Lo YMD, Tein MSC, Lau TK, Haines CJ, Leung TN, Poon PMK, Wainscoat JS, Johnson PJ, Chang AMZ, Hjelm NM. Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis. Am J Hum Genet. 1998;62:768–75.